Trackers

Copyright © 2025 LexisNexis

Trackers

Trackers monitor key cases, legislation, consultations, guidance documents, reports, opinions and other events for certain areas of law. See:

  1. •

    Life sciences cases tracker—UK is intended to be used to track the progress of UK cases relevant to the life sciences sector

  2. •

    Life sciences cases tracker—EU is intended to be used to track the progress of EU cases relevant to the life sciences sector

  3. •

    Life sciences tracker—UK is intended to be used to track the progress of UK legislative proposals and current consultations relevant to the life sciences sector

  4. •

    Life sciences tracker—EU is intended to be used to track the progress of EU legislative proposals and current consultations relevant to the life sciences sector

  5. •

    Patents tracker—UK is intended to be used to track the progress of key patent judgments, legislative proposals and consultations in the UK

  6. •

    Patents tracker—EU is intended to be used to track the progress of key patent judgments, legislative proposals

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Existing user? Sign-in TAKE A FREE TRIAL
Powered by Lexis+®
Latest Life Sciences News

MHRA launches consultation to evaluate the Medicines and Medical Devices Act 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation seeking stakeholder feedback on the operation and impact of medicines and medical devices legislation. The review, mandated under Part 6, Regulation 48 of the Medicines and Medical Devices Act 2021, examines four key regulations: the Human Medicines Regulations 2012, Medical Devices Regulations 2002, Medicines for Human Use (Clinical Trials) Regulations 2004, and Medicines and Medical Devices (Fees) Regulations. The consultation, running until 19 September 2025, aims to assess whether the legislation effectively protects public health without imposing unnecessary regulatory burdens. Findings will inform a report to be published by the Secretary of State for Health and Social Care.

European Parliament publishes study on AI and civil liability

The European Parliament’s Policy Department for Justice, Civil Liberties and Institutional Affairs has published a study examining the EU’s regulatory approach to civil liability for artificial intelligence (AI) systems. The study, commissioned at the request of the Committee on Legal Affairs, recommends implementing a strict liability regime for high-risk AI systems. It advocates for a single responsible operator model to prevent regulatory fragmentation across EU Member States and emphasises the importance of legal certainty, efficiency and harmonisation in the regulatory framework.

MHRA  launches world-first framework for decentralised manufacture of personalised medicines

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that the application date for groundbreaking new UK legislation has arrived from 23 July 2025. The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025, SI 87/2025 will provide the world's first regulatory framework that allows breakthrough personalised medicines such as cancer and immunotherapy (ie CAR-T) treatments to be prepared in small or individual batches. It aims to transform the manufacture of innovative medicines at the point of patient care.

EFRAG launches portal analysing 1st ESRS sustainability statements

The European Financial Reporting Advisory Group (EFRAG) has launched its 'EFRAG 2025 State of Play' portal, providing analysis of the first 656 European Sustainability Reporting Standards (ESRS) statements issued under the Corporate Sustainability Reporting Directive (CSRD). The portal includes a statistics dashboard and report repository showing only 10% of companies identified all ESRS standards as material, while 55% disclosed climate transition plans. The analysis will inform EFRAG's work on ESRS simplification following the European Commission's March 2025 mandate.

View Life Sciences by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Glossary—Latin legal terms

Glossary—Latin legal termsDespite attempts in recent years to simplify the language used in legal cases, there are still a number of Latin phrases commonly used in personal injury claims. The following Latin phrases are listed in alphabetical order:Latin
Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

Contributory negligence in personal injury claims

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Glossary—Latin legal terms

Glossary—Latin legal terms

Glossary—Latin legal termsDespite attempts in recent years to simplify the language used in legal cases, there are still a number of Latin phrases commonly used in personal injury claims. The following Latin phrases are listed in alphabetical order:Latin